4 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow Primary Mediastinal Large B-cell Lymphoma: new trials by email Literature Review of Primary Mediastinal Large B-cell Lymphoma trials Research Report on Primary Mediastinal Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma Ruxolitinib - Relapsed or Refractory Hodgkin Lymphoma, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | Samsung Medical Center | 20 | 2013-11-15 | 2018-11-01 |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Tazemetostat, Prednisolone - B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1) | Phase 1 / Phase 2 | Completed | Epizyme, Inc. | 400 | 2013-06-13 | 2024-03-26 |
| CT-011 MAb in DLBCL Patients Following ASCT CT-011 - Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse | Phase 2 | Completed | CureTech Ltd | 72 | 2007-10-01 | 2014-09-12 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 348 | 1993-05-08 | 2025-06-22 |
Lymphoma, Large B-Cell, Diffuse (3) · Recurrence (2) · Burkitt Lymphoma (1) · Hodgkin Disease (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Disease Attributes (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1)
Biopsy (1) · Cyclophosphamide (1) · Dioctyl Sulfosuccinic Acid (1) · Doxorubicin (1) · Etoposide (1) · Lactulose (1) · Laparotomy (1) · Magnetic Resonance Imaging (1) · Methylprednisolone (1) · Omeprazole (1) · Ondansetron (1) · Positron-Emission Tomography (1) · Prednisolone (1) · Prednisone (1) · Prochlorperazine (1)
CureTech Ltd (1) · Epizyme, Inc. (1) · National Cancer Institute (NCI) (1) · Samsung Medical Center (1)
United States (3) · Australia (1) · Canada (1) · France (1) · Germany (1) · India (1) · Israel (1) · Italy (1) · Poland (1) · South Korea (1) · Taiwan (1) · Ukraine (1) · United Kingdom (1)
Arnon Nagler, MD (1) · Leo I Gordon, MD (1) · Mark J Roschewski, M.D. (1) · Won Seog Kim, PhD (1)
PMID 23574119, PMID 24127452, PMID 24224624, PMID 25024303, PMID 29650362, PMID 29748435, PMID 30125215, PMID 31707975, PMID 33035457, PMID 34432874, PMID 35882475, PMID 37981564, PMID 39563886